Lauren Whelan
Overview
Explore the profile of Lauren Whelan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
6
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jin W, Deng Y, La Marca J, Lelliott E, Diepstraten S, Konig C, et al.
Nat Commun
. 2025 Jan;
16(1):974.
PMID: 39885149
Cas12a is a next-generation gene editing tool that enables multiplexed gene targeting. Here, we present a mouse model that constitutively expresses enhanced Acidaminococcus sp. Cas12a (enAsCas12a) linked to an mCherry...
2.
Lieschke E, Thomas A, Kueh A, Atkin-Smith G, Baldoni P, La Marca J, et al.
EMBO J
. 2024 Aug;
43(19):4406-4436.
PMID: 39160273
Investigating how transcription factors control complex cellular processes requires tools that enable responses to be visualised at the single-cell level and their cell fate to be followed over time. For...
3.
Diepstraten S, Yuan Y, La Marca J, Young S, Chang C, Whelan L, et al.
Cancer Cell
. 2024 Apr;
42(5):850-868.e9.
PMID: 38670091
TP53-mutant blood cancers remain a clinical challenge. BH3-mimetic drugs inhibit BCL-2 pro-survival proteins, inducing cancer cell apoptosis. Despite acting downstream of p53, functional p53 is required for maximal cancer cell...
4.
La Marca J, Aubrey B, Yang B, Chang C, Wang Z, Kueh A, et al.
Cell Death Differ
. 2023 Dec;
31(2):150-158.
PMID: 38097622
Whole-genome screens using CRISPR technologies are powerful tools to identify novel tumour suppressors as well as factors that impact responses of malignant cells to anti-cancer agents. Applying this methodology to...